Janux Therapeutics, Inc. (NASDAQ:JANX) Position Lifted by Ameriprise Financial Inc.

Ameriprise Financial Inc. grew its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 182.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,906 shares of the company’s stock after acquiring an additional 9,636 shares during the period. Ameriprise Financial Inc.’s holdings in Janux Therapeutics were worth $798,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. boosted its stake in Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after acquiring an additional 442 shares during the period. Rhumbline Advisers lifted its holdings in shares of Janux Therapeutics by 1.6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after purchasing an additional 599 shares during the last quarter. Kennedy Capital Management LLC lifted its holdings in shares of Janux Therapeutics by 7.9% in the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company’s stock worth $681,000 after purchasing an additional 928 shares during the last quarter. MetLife Investment Management LLC boosted its position in Janux Therapeutics by 5.8% during the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company’s stock valued at $926,000 after purchasing an additional 949 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in Janux Therapeutics by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock worth $596,000 after buying an additional 1,095 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Insider Buying and Selling

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $30.00, for a total transaction of $100,020.00. Following the sale, the insider now owns 82,139 shares in the company, valued at $2,464,170. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. acquired 110,206 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the purchase, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This trade represents a 1.10% increase in their position. The disclosure for this purchase can be found here. Insiders own 8.10% of the company’s stock.

Janux Therapeutics Price Performance

Shares of JANX opened at $25.01 on Tuesday. The firm’s 50 day moving average is $27.27 and its 200-day moving average is $38.33. Janux Therapeutics, Inc. has a 12-month low of $22.48 and a 12-month high of $71.71. The stock has a market capitalization of $1.48 billion, a P/E ratio of -21.38 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on JANX shares. Wedbush reiterated an “outperform” rating and issued a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Scotiabank cut their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Janux Therapeutics currently has a consensus rating of “Buy” and an average target price of $95.25.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.